This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prevention of contrast induced acute kidney injury

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • patients identified at being at risk of contrast induced-AKI (CI-AKI) should have a careful assessment of volume status and receive pre-procedure volume expansion with 0.9% sodium chloride or isotonic sodium bicarbonate if clinically indicated

Contrast-induced acute kidney injury (CI-AKI) secondary to radiological contrast media is uncommon in the general population

  • classically occurs within 72 hours of receiving the contrast media and usually recovers over the following five days
  • incidence increases significantly in patients with risk factors and is associated with an increased short and long-term mortality
  • acute kidney injury results from a combination of afferent arteriolar vasoconstriction and direct toxicity of the contrast media to the tubule epithelial cells

Preventing acute kidney injury in adults having iodine-based contrast media (2):

  • encourage oral hydration before and after procedures using intravenous iodine-based contrast media in adults at increased risk of contrast-induced acute kidney injury
    • before offering iodine-based contrast media to adults, assess their risk of acute kidney injury but do not delay emergency imaging. Be aware that increased risk is associated with:
      • chronic kidney disease (adults with an eGFR less than 40 ml/min/1.73m2 are at particular risk)
      • diabetes but only with chronic kidney disease (adults with an eGFR less than 40 ml/ min/1.73m2 are at particular risk)
      • heart failure
      • renal transplant
      • age 75 years or over
      • hypovolaemia
      • increasing volume of contrast agent
      • intra-arterial administration of contrast medium with first-pass renal exposure


  • for inpatients having iodine-based contrast media, consider intravenous volume expansion with either isotonic sodium bicarbonate or 0.9% sodium chloride if:
    • they are at particularly high risk, for example, if:
      • they have an eGFR less than 30 ml/min/1.73m2
      • they have had a renal transplant
      • a large volume of contrast medium is being used (for example, higher than the standard diagnostic dose or repeat administration within 24 hours)
      • intra-arterial administration of contrast medium with first-pass renal exposure is being used
  • consider temporarily stopping ACE inhibitors and ARBs in adults having iodine based contrast media if they have chronic kidney disease with an eGFR less than 40 ml/min/1.73m2


  • discuss the person's care with a nephrology team before offering iodine-based contrast media to adults on renal replacement therapy, including people with a renal transplant, but do not delay emergency imaging for this

Potentially nephrotoxic medications such as non-steroidal anti-inflammatory drugs and aminoglycosides should be withheld or avoided. Currently there is insufficient evidence to support the routine discontinuation of angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) in stable outpatients (1,2)

Metformin is not nephrotoxic but is exclusively excreted via the kidneys (1,3)

  • patients on metformin who develop AKI are at risk of developing lactic acidosis
  • advice from the Royal College of Radiologists is that there is no need to stop metformin after receiving contrast if the serum creatinine is within the normal range and/or eGFR > 60 ml/min/1.73m2
  • if serum creatinine is above the normal reference range or eGFR is < 60 ml/min/1.73m2, any decision to stop it for 48 hours should be made in consultation with the referring clinician

Notes:

  • first-pass renal exposure is when the contrast medium reaches the renal arteries in a relatively undiluted form, for example, through injection into the left heart, thoracic and suprarenal abdominal aorta, or the renal arteries (2)
  • patients identified as at high risk of CI-AKI should be discussed with a renal physician to assess the individual risk/benefit to the patient (1)
    • recognised that in some patients the risk of CI-AKI is outweighed by the potential benefit from the contrast study
  • Renal Association guidance also lists
    • atherosclerotic peripheral vascular disease; liver disease; and sepsis as risk factors for contrast induced kidney disease (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.